COVID-19 vaccine safety and effectiveness at 3 months in institutionalized old people.

ingentiumby ingentium

In Vaccines Literature.

Publication date: Dec 23, 2024

Older age and associated comorbid conditions increase the risk of severe form of COVID-19 and death. The SARS-CoV-2 vaccination campaign began in France in December 2020 targeting institutionalized older population before having been evaluated in this population. The objective of our study was to assess the tolerability of vaccination 21 days (D21) and 90 days after the first vaccination (D90) in institutionalized old people. Secondary objective was to assess its effectiveness (mortality, hospitalization and occurrence of COVID) at D21 and D90. People living in nursing homes or in long-term hospitalization facilities in France were included 12-2020-06-2021. They were divided into SARS-CoV-2 vaccinated and unvaccinated groups. Vaccine tolerability was prospectively assessed by the occurrence of health events at D21 and D90 (local and systemic side effects, geriatric syndromes, cardiovascular events). Vaccine efficacy was assessed by the occurrence of COVID-19 and serious adverse events (unscheduled hospitalization and all-cause mortality). The mean age of the 2595 participants was 86 years, 83% received COVID-19 vaccine. There were no significant difference between the vaccinated and unvaccinated for systemic or local adverse events at D21 and D90. At D90, vaccinated participants had significantly fewer SARS-CoV-2 infections (odds ratio (95% confidence interval) = 0. 35 (0. 22-0. 58)), fewer deaths or hospitalizations (0. 50 (0. 31-0. 81)), fewer cardiovascular events (0. 28 (0. 12-0. 64)) and fewer pressure ulcers (0. 38 (0. 17-0. 88)). In this prospective cohort study, COVID-19 vaccine in a very old institutionalized geriatric population had a reassuring safety profile and a protective effect on COVID-19, hospitalizations and deaths, cardiovascular events and pressure ulcers.

Open Access PDF

Concepts Keywords
Covid COVID-19
France COVID-19 vaccine
Severe Geriatric population
Vaccinated Institutionalization
Nursing home

Semantics

Type Source Name
disease MESH COVID-19
disease MESH death
disease MESH syndromes
disease MESH pressure ulcers
pathway REACTOME Reproduction
disease MESH infections
drug DRUGBANK L-Valine
drug DRUGBANK L-Isoleucine
drug DRUGBANK Nonoxynol-9
disease MESH obesity
disease MESH liver diseases
disease IDO history
disease MESH allergy
disease MESH neurocognitive disorders
disease MESH dementia
disease MESH depression
disease MESH hypertension
disease MESH heart failure
disease MESH atrial fibrillation
disease MESH stroke
disease MESH cancer
disease MESH chronic obstructive pulmonary disease
disease MESH respiratory failure
disease MESH edema
disease MESH hematoma
disease MESH anorexia
disease MESH arthralgia
disease MESH myocardial infarction
disease MESH venous thrombosis
disease MESH pulmonary embolism
disease MESH autoimmune disease
disease MESH Bell’s palsy
disease MESH confusional state
disease MESH hallucinations
disease MESH dehydration
drug DRUGBANK MK-212
disease MESH respiratory diseases
disease MESH diabetes mellitus
disease MESH ulcers
disease MESH delirium
drug DRUGBANK Trestolone
disease MESH comorbidity
disease IDO infection
disease MESH malnutrition
disease MESH cognitive disorders
drug DRUGBANK Coenzyme M
pathway REACTOME Immune System
disease MESH influenza
disease MESH morbidities
drug DRUGBANK Albendazole
drug DRUGBANK Diethylstilbestrol
drug DRUGBANK Cycloserine
disease MESH pneumonia
drug DRUGBANK Carboxyamidotriazole
drug DRUGBANK Lopinavir
drug DRUGBANK Ritonavir
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Lipoic Acid
disease MESH critically ill
drug DRUGBANK Ribavirin
drug DRUGBANK Natural alpha interferon
drug DRUGBANK Methionine
disease MESH severe Acute Respiratory Syndrome
drug DRUGBANK Favipiravir
drug DRUGBANK Baloxavir marboxil
disease IDO symptom
disease MESH frailty

Original Article

(Visited 1 times, 1 visits today)